# Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

> **NCT02787551** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 514 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Insulin glargine/lixisenatide fixed ratio combination
- **DRUG:** liraglutide
- **DRUG:** exenatide
- **DRUG:** exenatide extended-release
- **DRUG:** albiglutide
- **DRUG:** dulaglutide
- **DRUG:** Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)

## Key facts

- **NCT ID:** NCT02787551
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-06
- **Primary completion:** 2018-05-25
- **Final completion:** 2018-11-17
- **Target enrollment:** 514 (ACTUAL)
- **Last updated:** 2022-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02787551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02787551, "Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02787551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*